ImmunityBio (IBRX) announced that the U.S. Food and Drug Administration, FDA, has granted Expanded Access authorization for the use of its Cancer BioShield platform, anchored by ANKTIVA, to treat lymphopenia in adult patients with refractory or relapsed solid tumors independent of tumor type who have progressed after first-line standard-of-care treatment, chemotherapy, radiation, or immunotherapy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- ImmunityBio to launch Cancer BioShield in the Middle East
- Piper upgrades ImmunityBio on Anktiva expansion opportunities
- ImmunityBio upgraded to Overweight from Neutral at Piper Sandler
- Short Report: Bears not fearing rebound in Rocket, Avis Budget shares
- ImmunityBio Sees Revenue Surge Amid Strong Sales Momentum